Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Hans Proquitté - , Humboldt University of Berlin (Author)
  • Thekla Dushe - , Humboldt University of Berlin (Author)
  • Hannes Hammer - , Humboldt University of Berlin (Author)
  • Mario Rüdiger - , Department of Paediatrics, Center for feto/neonatal Health, Charité – Universitätsmedizin Berlin, Humboldt University of Berlin (Author)
  • Gerd Schmalisch - , Humboldt University of Berlin (Author)
  • Roland R. Wauer - , Humboldt University of Berlin (Author)

Abstract

Introduction: Natural surfactants have been shown to be superior to synthetic surfactants in the treatment of neonatal respiratory distress syndrome (RDS). In Germany, Alveofact® (A) and Curosurf® (C) are the most frequently used natural surfactant preparations. The aim of this retrospective, observational study was to compare the effects of A and C on gas exchange and outcome in premature infants. Methods: During a 5-year period in our neonatal intensive care unit (NICU), 187 premature infants were treated with surfactant, with 82 receiving A and 105 receiving C. We recorded FIO2 and gas exchange (PaO2/FIO2 ratio, PaCO2, SaO2) during the first 72 h after surfactant application and the incidence of outcome parameters at day 28 (bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH grade III or IV), patent ductus arteriosus (PDA), pneumothorax, necrotizing enterocolites (NEC) and death). The differences between the patient groups were assessed by ANOVA or the calculation of relative risks. Bonferroni correction was used for multiple comparisons. Results: There were no statistically significant differences between infants treated with A and C in mean gestational age (28.4 vs. 28.4 weeks), birth weight (1210 vs.1258 g) and time of first surfactant application (60 vs. 90 min postnatal). We observed no significant between group differences in course of FIO2 and blood gases, or in incidence at day 28 of BPD (41.7% vs. 42.8%), IVH III/IV (18.3% vs. 14.3%), pneumothorax (9.8% vs. 4.8%), PDA (23.2% vs. 21.9%), PVL (7.3% vs. 9.5%) and death (17% vs. 17.1%). There were also no statistically significant differences in the subgroup of infants <28 weeks. The lower incidence of NEC in A compared with C (1.2% vs. 10.5%, P = 0.01) was not statistically significant after Bonferroni correction. Conclusion: Independent of gestational age no significant difference in the clinical efficacy of A and C was observed.

Details

Original languageEnglish
Pages (from-to)169-176
Number of pages8
JournalRespiratory medicine
Volume101
Issue number1
Publication statusPublished - Jan 2007
Peer-reviewedYes

External IDs

PubMed 16698258

Keywords

ASJC Scopus subject areas

Keywords

  • Gas exchange, Outcome, Premature infant, Respiratory distress syndrome, Surfactant